Table 2.
One-stage individual participants dataset meta-analysis for all-cause mortality and cardiovascular or cerebrovascular events
| Number of studies | Testosterone treatment group | Placebo group | OR (95% CI) | p value | ||
|---|---|---|---|---|---|---|
| Mortality from any cause | ||||||
| Number of participants* | 14 | 6/1621 (0·4%) | 12/1537 (0·8%) | 0·46 (0·17–1·24) | 0·13 | |
| Myocardial Infarction | 3 | 2/6 (33·3%) | 2/12 (16·7%) | .. | .. | |
| Cancer | 1 | 0 | 3/12 (25·0%) | .. | .. | |
| Ruptured aortic aneurysm | 1 | 0 | 1/12 (8·3%) | .. | .. | |
| Constrictive pericarditis | 1 | 1/6 (16·7%) | 0 | .. | .. | |
| Multiple organ failure | 1 | 1/6 (16·7%) | 0 | .. | .. | |
| Venous thromboembolism | 1 | 0 | 1/12 (8·3%) | .. | .. | |
| Unknown | 3 | 2/6 (33·3%) | 5/12 (41·7%) | .. | .. | |
| Cardiovascular or cerebrovascular events | ||||||
| Number of participants† | 13 | 120/1601 (7·5) | 110/1519 (7·2) | 1·07 (0·81, 1·42) | 0.62 | |
| Total number of events | 13 | 182 | 183 | .. | .. | |
| Number of participants with a cardiovascular event | 11 | 107/120 (89·2%) | 105/110 (95·5%) | .. | .. | |
| Total number of cardiovascular events‡ | 11 | 166 | 176 | .. | .. | |
| Arrhythmia | 6 | 52/166 (31·3%) | 47/176 (26·7%) | .. | .. | |
| Coronary heart disease | 6 | 33/166 (19·9%) | 33/176 (18·8%) | .. | .. | |
| Heart failure | 6 | 22/166 (13·3%) | 28/176 (15·9%) | .. | .. | |
| Myocardial infarction | 7 | 10/166 (6·0%) | 16/176 (9·1%) | .. | .. | |
| Valvular heart disease | 2 | 18/166 (10·8%) | 12/176 (6·8%) | .. | .. | |
| Peripheral vascular disease | 4 | 8/166 (4·8%) | 14/176 (8·0%) | .. | .. | |
| Stable angina | 5 | 7/166 (4·2%) | 7/176 (4·0%) | .. | .. | |
| Aortic aneurysm§ | 5 | 6/166 (3·6%) | 7/176 (4·0%) | .. | .. | |
| New angina | 3 | 5/166 (3·0%) | 5/176 (2·8%) | .. | .. | |
| Unstable angina | 3 | 2/166 (1·2%) | 4/176 (2·3%) | .. | .. | |
| Aortic dissection | 1 | 2/166 (1·2%) | 0 | .. | .. | |
| Atherosclerosis | 1 | 1/166 (0·6%) | 1/176 (0·6%) | .. | .. | |
| Cardiac arrest | 2 | 0 | 2/176 (1·1%) | .. | .. | |
| Number of participants with a cerebrovascular event | 11 | 15/120 (12·5%) | 7/110 (6·4%) | .. | .. | |
| Total number of cerebrovascular events‡ | 11 | 16 | 7 | .. | .. | |
Data are n/N (%), unless otherwise specified. For one study38 outcomes were reported up to 3 years and the date of events could not be confirmed. OR=odds ratio.
Of the 14 studies, eight reported no deaths11, 16, 39, 40, 41, 42, 43, 44 and six reported deaths.15, 17, 38, 45, 46, 47 We were unable to confirm whether any deaths occurred for the remaining three studies;48, 49, 50 therefore, they were not included.
Of the 13 studies, two42, 43 reported no cardiovascular or cerebrovascular events. We were unable to confirm whether cardiovascular or cerebrovascular events occurred for the remaining four studies.44, 48, 49, 50
Some participants had more than one event.
One event was a ruptured aortic aneurysm.